Coverage
-
January 05, 2024
A Ninth Circuit panel on Friday denied drugmaker Valeant Pharmaceuticals' request to review its decision to revive a False Claims Act suit accusing Valeant of fraudulently obtaining a patent to extend its monopoly on the drug Apriso.
3 other articles on this case.
View all »